PTC Therapeutics Faces FDA Rejection On Rare Disease Treatment Over Efficacy Concerns
The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) on Tuesday related to PTC Therapeutics, Inc.‘s (NASDAQ:PTCT) New Drug Application (NDA) for vatiquinone for Friedreich’s ataxia.
Benzinga ·